ArticleJournal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology2013
Development of novel anti-Kv 11.1 antibody-conjugated PEG-TiO
Article in Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Photoinduced Immobilization on Two-Dimensional Nano Borophene Spatially Orients Capture Antibody for Highly Sensitive Biological Interactions.ACS central science · 2025Article
- Retraction Note: Development of novel anti-Kv 11.1 antibody-conjugated PEG-TiOJournal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology · 2025Article
- Promoting proliferation and tumorigenesis of breast cancer: KCND2's significance as a prognostic factor.Functional & integrative genomics · 2023Article
- Targeting Ion Channels for Cancer Treatment: Current Progress and Future Challenges.Reviews of physiology, biochemistry and pharmacology · 2022Review
- Roles of voltage‑gated potassium channels in the maintenance of pancreatic cancer stem cells.International journal of oncology · 2021Article
- Ion Channel Signature in Healthy Pancreas and Pancreatic Ductal Adenocarcinoma.Frontiers in pharmacology · 2020Review
- Antibodies Targeting KBioelectricity · 2019Article
- Generation and characterization of novel recombinant anti-hERG1 scFv antibodies for cancer molecular imaging.Oncotarget · 2018Article
- New photosensitizers for photodynamic therapy.The Biochemical journal · 2016Review
- Targeted polyethylene glycol gold nanoparticles for the treatment of pancreatic cancer: from synthesis to proof-of-concept in vitro studies.International journal of nanomedicine · 2016Article
- hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma.British journal of cancer · 2015Article
- Multifunction hexagonal liquid-crystal containing modified surface TiO2 nanoparticles and terpinen-4-ol for controlled release.International journal of nanomedicine · 2015Article
- Review
Corrections and comments
- Correction · 2022-07-11Error in Data · Updated to Retraction · · see also: https://mis.cnrs.fr/wp-content/uploads/2025/05/Recommandations.pdf
- Retraction · 2025-02-27Concerns/Issues about Image · Investigation by Company/Institution · Investigation by Journal/Publisher · Objections by Author(s) · Unreliable Results and/or Conclusions · Upgrade/Update of Prior Notice(s) · · see aslo: https://pubpeer.com/publications/90304346FB0E8D3B1EFF78FAE11256 and https://mis.cnrs.fr/wp-content/uploads/2025/05/Recommandations.pdf
- Retracted
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Titanium dioxide (TiO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.